The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Sigma Planning Corp reduced its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.0% during the fourth quarter, according to its most recent disclosure with the Securities and ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...